IP Library Granted Patent US 8,920,921
Granted Patent B2
US 8,920,921 · App. 13/221,415 · Granted Dec 30, 2014

Terpolymer blends and their use as pressure-sensitive adhesives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,920,921
App. No.
13/221,415
Granted
Dec 30, 2014
Kind
B2
Abstract

Disclosed herein are blends prepared from polyester terpolymers that function as pressure-sensitive adhesives. The disclosed articles comprise the terpolymer blends adhered to a release liner. The disclosed implant devices comprise the pressure-sensitive adhesive blend adhered to a surface thereof. The pressure-sensitive adhesive blend can promote adhesion of the implant device to a location in a subject.

Claims (44)

1. An article, comprising:

a pressure-sensitive adhesive (PSA) having a first adhesive surface and an opposing second adhesive surface, the pressure-sensitive adhesive (PSA) comprising

(A) the blend comprising:

(a) a first poly(D,L-lactide-co-glycolide-co-ε-caprolactone) having a molecular weight (M w ) of from 75,000 to 250,000 Daltons and a polydispersity index (PDI) of less than 2.0, and

(b) a second poly(D,L-lactide-co-glycolide-co-e-caprolactone) having a molecular weight (M w ) of 60,000 to 130,000 Daltons and a polydispersity index (PDI) of less than 2.0;

wherein the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a molecular weight (M w ) that is less than the first poly(D,L-lactide-co-glycolide-co-ε-caprolactone); and

wherein the weight ratio of the first poly(D,L-lactide-co-glycolide-co-ε-caprolactone) to the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) is from about 90:10 to about 60:40, or

(B) the blend comprising:

(a) a third poly(D,L-lactide-co-glycolide-co-ε-caprolactone) having a molecular weight of from 75,000 to 250,000 Daltons and a polydispersity index (PDI) of less than 2.0, and

(b) a poly(D,L-lactide-co-glycolide-co-mPEG) having a molecular weight of less than 25,000 Daltons and a polydispersity index (PDI) of less than 2.0; and

wherein the weight ratio of the poly(D,L-lactide-co-glycolide-co-ε-caprolactone) to the poly(D,L-lactide-co-glycolide-co-mPEG) is from about 95:5 to about 75:25; and

a release liner having a surface thereof adhered to the first adhesive surface of the pressure-sensitive adhesive.

2. The article of claim 1 , wherein the weight ratio of the first poly(D,L-lactide-co-glycolide-co-c-caprolactone) to the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) is from about 85:15 to about 70:30.

3. The article of claim 1 , wherein the first poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a molecular weight (M w ) of from 100,000 to 130,000 Daltons.

4. The article of claim 1 , wherein the first poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a polydispersity index (PDI) ranging from 1.5 to 1.8.

5. The article of claim 1 , wherein the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a polydispersity index (PDI) ranging from 1.5 to 1.8.

6. The article of claim 1 wherein the weight ratio of the third poly(D,L-lactide-co-glycolide-co-ε-caprolactone) to the poly(D,L-lactide-co-glycolide-co-mPEG) is from about 90:10 to about 85:15.

7. The article of claim 1 , wherein the third poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a molecular weight (M w ) of from 100,000 to 130,000 Daltons.

8. The article of claim 1 , wherein the poly(D,L-lactide-co-glycolide-co-mPEG) has a molecular weight (M w ) of from 10,000 to 20,000 Daltons.

9. The article of claim 1 , wherein the third poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a polydispersity index (PDI) ranging from 1.5 to 1.8.

10. The article of claim 1 , wherein the poly(D,L-lactide-co-glycolide-co-mPEG) has a polydispersity index (PDI) ranging from 1.4 to 1.7.

11. An implant device comprising

a substrate

a planar layer of a pressure-sensitive adhesive (PSA) adhered to a surface of the substrate, the PSA comprising a blend,

(A) the blend comprising:

(a) a first poly(D,L-lactide-co-glycolide-co-ε-caprolactone) having a molecular weight (M w ) of from 75,000 to 250,000 Daltons and a polydispersity index (PDI) of less than 2.0, and

(b) a second poly(D,L-lactide-co-glycolide-co-e-caprolactone) having a molecular weight (M w ) of 60,000 to 130,000 Daltons or less and a polydispersity index (PDI) of less than 2.0;

wherein the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) has a molecular weight (M w ) that is less than the first poly(D,L-lactide-co-glycolide-co-ε-caprolactone); and

wherein the weight ratio of the first poly(D,L-lactide-co-glycolide-co-ε-caprolactone) to the second poly(D,L-lactide-co-glycolide-co-e-caprolactone) is from about 90:10 to about 60:40, or

(B) the blend comprising:

(a) a poly(D,L-lactide-co-glycolide-co-ε-caprolactone) having a molecular weight of from 75,000 to 250,000 Daltons and a polydispersity index (PDI) of less than 2.0, and

(b) a poly(D,L-lactide-co-glycolide-co-mPEG) having a molecular weight of less than 25,000 Daltons and a polydispersity index (PDI) of less than 2.0; and

wherein the weight ratio of the poly(D,L-lactide-co-glycolide-co-ε-caprolactone) to the poly(D,L-lactide-co-glycolide-co-mPEG) is from about 95:5 to about 75:25.

12. The implant device of claim 11 , the blend forming a layer wherein the substrate further comprises a bioactive layer adhered to a surface of the blend layer, the bioactive layer comprising a bioactive agent dispersed within a poly(D,L-lactide-co-glycolide) having a molecular weight of 20,000 Daltons or less.

13. The implant device of claim 11 , wherein the substrate is flexible.

14. The implant device of claim 11 , wherein the substrate is biodegradable.

15. The implant device of claim 11 , wherein the substrate comprises poly(L-lactide-co-ε-caprolactone).

16. The implant device of claim 11 , wherein the substrate comprises titanium or stainless steel.

17. The implant device of claim 11 , wherein the substrate has a first surface and an opposing second surface and wherein the blend is disposed on the first surface.

18. The implant device of claim 17 , wherein the substrate is a disk-shaped substrate.

19. The implant device of claim 17 , wherein the first and second surfaces are planar.

20. The implant device of claim 17 , wherein the second surface is parallel to the first surface.

21. The implant device of claim 17 , further comprising an annular edge surface contiguous with the first and second surfaces.

22. The implant device of claim 17 , further comprising a bioactive layer comprising a bioactive agent dispersed within a poly(D,L-lactide-co-glycolide) having a molecular weight of 20,000 Daltons or less, wherein the bioactive layer is adhered to the second surface.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS MD, LLC
Reel/Frame 073894/0058 →